• Slide Title

    Write your caption here

    Button
  • Slide Title

    Write your caption here

    Button
  • Slide Title

    Write your caption here

    Button
  • Slide Title

    Write your caption here

    Button

News feed

Developing unique therapeutics for the treatment of Traumatic Brain Injury (TBI), Repeated Concussion, and Other Serious Neurological Conditions.
Annual General Meeting 2015

News – Phase 1 Clinical Studies Planning Well Advanced

PresSura Neuro is pleased to report that it has progressed its innovative compound, EU-C-001, for the treatment of Intracranial Pressure  (ICP) in Traumatic Brain Injury (TBI), as well as long term outcome after Concussion (Post Concussion Syndrome (PCS)) and Chronic Traumatic Encephalopathy (CTE). The manufacturing of the drug substance is well advanced and preclinical studies with the drug are in progress. 
PresSure has commenced preparation for a Phase 1 safety study for EU-C-001, for the treatment of TBI, concussion/CTE. (20 March 2015).

Brief

PresSura's Scientists have discovered two distinct mechanisms that are involved in either the development of PCS and Chronic Traumatic Encephalopathy (CTE) after repeated concussion as well the increase of Intracranial Pressure following Traumatic Brain Injury (TBI).  

PressSura's drug showed promising activity in animal models of both concussion / CTE and ICP following a TBI.

Location

To find out more about what we do, browse the rest of our site or contact us at info@pressuraneuro.com.au

Share by: